terfenadine (Seldane)

Introduction

Tradename: Seldane. FDA approved in 1985. Withdrawn from US market in 1998.

Contraindications

Caution: do not use with liver failure

pregnancy category = c

safety in lactation = -

Dosage

60 mg PO BID 60 mg.

Pharmacokinetics

• Fexofenadine is active metabolite

elimination via liver

elimination via kidney

Adverse effects

• QT-prolongation

• drug adverse effects of H1 receptor antagonists

Drug interactions

• erythromycin
• ketoconazole

More general terms

• H1 receptor antagonist (antihistamine)
• piperidine

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5405